2. Academic Validation
  3. Clinical and metabolomics analysis of hepatocellular carcinoma patients with diabetes mellitus

Clinical and metabolomics analysis of hepatocellular carcinoma patients with diabetes mellitus

  • Metabolomics. 2019 Nov 26;15(12):156. doi: 10.1007/s11306-019-1619-x.
Hongping Xia 1 2,  Jianxiang Chen 3,  Karthik Sekar 4,  Ming Shi 5,  Tian Xie 3,  Kam M Hui 6 7 8 9 10 11
Affiliations

Affiliations

  • 1 Department of Pathology, School of Basic Medical Sciences & Sir Run Run Hospital & State Key Laboratory of Reproductive Medicine & Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing, China. [email protected].
  • 2 Laboratory of Cancer Genomics, Division of Cellular and Molecular Research, National Cancer Centre, Singapore, Singapore. [email protected].
  • 3 Holistic Integrative Pharmacy Institutes (HIPI), Hangzhou Normal University, Hangzhou, China.
  • 4 Laboratory of Cancer Genomics, Division of Cellular and Molecular Research, National Cancer Centre, Singapore, Singapore.
  • 5 Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, China.
  • 6 Department of Pathology, School of Basic Medical Sciences & Sir Run Run Hospital & State Key Laboratory of Reproductive Medicine & Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing, China. [email protected].
  • 7 Laboratory of Cancer Genomics, Division of Cellular and Molecular Research, National Cancer Centre, Singapore, Singapore. [email protected].
  • 8 Holistic Integrative Pharmacy Institutes (HIPI), Hangzhou Normal University, Hangzhou, China. [email protected].
  • 9 Institute of Molecular and Cell Biology, A*STAR, Biopolis Drive Proteos, Singapore, Singapore. [email protected].
  • 10 Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. [email protected].
  • 11 Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore, Singapore. [email protected].
PMID: 31773292 DOI: 10.1007/s11306-019-1619-x
Abstract

Introduction: Diabetes and Cancer are among the most frequent causes of death worldwide. Recent epidemiological findings have indicated a link between diabetes and Cancer in several organs, particularly the liver. A number of epidemiological studies have demonstrated that diabetes is an established independent risk factor for hepatocellular carcinoma (HCC). However, the metabolites connecting diabetes and HCC remains less well understood.

Objectives: The study aimed to identify clinical and metabolomics differences of HCC from patients with/without diabetes using comprehensive global metabolomics analysis.

Methods: Metabolite profiling was conducted with the Metabolon platform for 120 human diabetes/non-diabetes HCC tumor/normal tissues. Standard statistical analyses were performed using the Partek Genomics Suite on log-transformed data. Principal component analysis (PCA) was conducted using all and dysregulated metabolites.

Results: We identified a group of metabolites that are differentially expressed in the tumor tissues of diabetes HCC compared to non-diabetes HCC patients. Meanwhile, we also identified a group of metabolites that are differentially expressed in the matched normal liver tissues of diabetes HCC compared to non-diabetes HCC patients. Some metabolites are consistently dysregulated in the tumor or matched normal tissues of HCC with or without diabetes. However, some metabolites, including 2-hydroxystearate, were only overexpressed in the tumor tissues of HCC with diabetes and associated with the glucose level.

Conclusion: Metabolic profiling identifies distinct dysregulated metabolites in HCC patients with/without diabetes.

Keywords

Diabetes; Hepatocellular carcinoma; Metabolites; Metabolomics; Principal component analysis.

Figures
Products